RC
BIOA

RegentAtlantic Capital’s BioAmber Inc. BIOA Stock Holding History

RegentAtlantic Capital’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-520
Closed -$4.36K – 1114
2014
Q4 		$4.36K Buy
+520
New +$4.73K ﹤0.01% 1032

Other funds holding BIOA

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RegentAtlantic Capital's BIOA Position: Q1 2015 in Review

RegentAtlantic Capital sold out of BioAmber Inc. (BIOA) in Q1 2015, closing a stake of 520 shares — an estimated $4.36K sold.

RegentAtlantic Capital first reported a position in BIOA in Q4 2014 and held it in 1 quarter. The position peaked at $4.36K in Q4 2014. 35 funds tracked by Wall St. Rank hold BIOA as of Q1 2015.

  • RegentAtlantic Capital reported no remaining BioAmber Inc. position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 520 BioAmber Inc. shares in Q1 2015, an estimated $4.36K.
  • RegentAtlantic Capital first reported a position in BioAmber Inc. in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's BioAmber Inc. position peaked at $4.36K in Q4 2014.
  • 35 funds tracked by Wall St. Rank held BioAmber Inc. as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.